These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 28013105)

  • 1. The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50.
    Uchida T; Hagihara M; Hua J; Inoue M
    Leuk Res; 2017 Feb; 53():35-38. PubMed ID: 28013105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
    Pleyer L; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl-Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Geissler D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
    J Hematol Oncol; 2016 Apr; 9():39. PubMed ID: 27084507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.
    Voso MT; Niscola P; Piciocchi A; Fianchi L; Maurillo L; Musto P; Pagano L; Mansueto G; Criscuolo M; Aloe-Spiriti MA; Buccisano F; Venditti A; Tendas A; Piccioni AL; Zini G; Latagliata R; Filardi N; Fragasso A; Fenu S; Breccia M;
    Eur J Haematol; 2016 Apr; 96(4):344-51. PubMed ID: 26018238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.
    Arenillas L; Calvo X; Luño E; Senent L; Alonso E; Ramos F; Ardanaz MT; Pedro C; Tormo M; Marco V; Montoro J; Díez-Campelo M; Brunet S; Arrizabalaga B; Xicoy B; Andreu R; Bonanad S; Jerez A; Nomdedeu B; Ferrer A; Sanz GF; Florensa L
    J Clin Oncol; 2016 Sep; 34(27):3284-92. PubMed ID: 27382099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An analysis of 97 previously diagnosed de novo adult acute erythroid leukemia patients following the 2016 revision to World Health Organization classification.
    Qiu S; Jiang E; Wei H; Lin D; Zhang G; Wei S; Zhou C; Liu K; Wang Y; Liu B; Liu Y; Gong B; Gong X; Feng S; Mi Y; Han M; Wang J
    BMC Cancer; 2017 Aug; 17(1):534. PubMed ID: 28793875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
    Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
    Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
    Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
    Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.
    Vidal V; Robert G; Goursaud L; Durand L; Ginet C; Karsenti JM; Luciano F; Gastaud L; Garnier G; Braun T; Hirsch P; Raffoux E; Nloga AM; Padua RA; Dombret H; Rohrlich P; Ades L; Chomienne C; Auberger P; Fenaux P; Cluzeau T
    Oncotarget; 2017 Jul; 8(29):47103-47109. PubMed ID: 28514758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
    Thepot S; Boehrer S; Seegers V; Prebet T; Beyne-Rauzy O; Wattel E; Delaunay J; Raffoux E; Hunault M; Jourdan E; Chermat F; Sebert M; Kroemer G; Fenaux P; Adès L;
    Leuk Res; 2014 Dec; 38(12):1430-4. PubMed ID: 25449687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.
    Meers S; Selleslag D; Potier H; Glasmacher A; Mineur P; Voelter V
    Curr Med Res Opin; 2015 Jan; 31(1):35-42. PubMed ID: 25317956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloblastic leukemia.
    Molina CA; Rodríguez MJ; de Marcos NS; Font P
    Adv Ther; 2011 Mar; 28 Suppl 3():10-6. PubMed ID: 21431629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythroblast predominance without CD41/cyCD41-positive blasts predicts favorable prognosis in patients with myelodysplastic syndromes and acute myeloid leukemias treated with azacitidine.
    Matsuoka A; Tanibuchi M; Yamazaki I; Taoka T
    Int J Hematol; 2022 Jun; 115(6):852-859. PubMed ID: 35275354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shifting of erythroleukemia to myelodysplastic syndrome according to the revised WHO classification: Biologic and cytogenetic features of shifted erythroleukemia.
    Ryu S; Park HS; Kim SM; Im K; Kim JA; Hwang SM; Yoon SS; Lee DS
    Leuk Res; 2018 Jul; 70():13-19. PubMed ID: 29729583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.
    Sébert M; Komrokji RS; Sekeres MA; Prebet T; Cluzeau T; Santini V; Gyan E; Sanna A; Ali NH; Hobson S; Eclache V; List A; Fenaux P; Adès L
    Leuk Res; 2017 Dec; 63():72-77. PubMed ID: 29112938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine.
    Jabbour E; Kantarjian H; O'Brien S; Kadia T; Malik A; Welch MA; Teng A; Cortes J; Ravandi F; Garcia-Manero G
    Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):592-6. PubMed ID: 23790798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effective azacitidine treatment for myelodysplastic syndrome transformed from essential thrombocythemia].
    Iizuka H; Yoshimi A; Yamamoto G; Masuda A; Nannya Y; Ichikawa M; Yatomi Y; Kurokawa M
    Rinsho Ketsueki; 2013 May; 54(5):468-72. PubMed ID: 23727686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
    Cabrero M; Jabbour E; Ravandi F; Bohannan Z; Pierce S; Kantarjian HM; Garcia-Manero G
    Leuk Res; 2015 May; 39(5):520-4. PubMed ID: 25828745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.
    Craddock C; Labopin M; Robin M; Finke J; Chevallier P; Yakoub-Agha I; Bourhis JH; Sengelov H; Blaise D; Luft T; Hallek M; Kröger N; Nagler A; Mohty M
    Haematologica; 2016 Jul; 101(7):879-83. PubMed ID: 27081178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late hematological improvement of myelodysplastic syndrome following treatment with 5-azacitidine therapy.
    Takaoka K; Hangaishi A; Ito A; Morioka T; Kida M; Usuki K
    Intern Med; 2014; 53(19):2241-3. PubMed ID: 25274238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.